Dudediligence.

Skye Bioscience, Inc

SKYENASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$3.9MSep ’24−$9.7MDec ’24−$11.1MMar ’25−$17.6MJun ’25−$12.8MSep ’25−$14.4MDec ’25−$12.5MMar ’26−$10.8MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating income−$7.8M−$18.3M−$34.7M−$30.2M−$58.2M
Net income−$8.5M−$19.5M−$37.6M−$26.6M−$55.9M
Operating cash flow−$6.5M−$12.7M−$14.0M−$25.2M−$43.1M
Free cash flow−$6.6M−$12.8M−$14.0M−$26.8M−$43.1M
Cash$9.0M$1.2M$1.3M$68.4M$5.9M
Shares outstanding476.1M3.7M12.3M31.0M33.4M